Immunoprecipitation

Protein A resins market to register an appreciable CAGR via antibody purification applications, clinical research laboratories to drive the end-use landscape over 2018-2024

Posted on Updated on

The rise of biologics in antibody engineering & drug development has called for unprecedented growth in the global protein A resins market. The considerable surge in regulatory approvals of monoclonal antibodies from the last few years to combat the robust product demand has also had a commendable implication on the growth statistics of protein A resins market. Monoclonal antibodies, owing to their specificity, efficacy, and stability have become increasingly favorable as therapeutic tools for a variety of conditions, from autoimmune diseases to cancer. Given the popularity of these antibodies for research & diagnostic applications, analysts deem the commercialization potential of global protein A resins market to further tread along a lucrative roadmap in the years ahead.

India Protein A Resins Market, By Application, 2013 – 2024 (USD Million)

India Protein A Resins Market, By Application, 2013 – 2024 (USD Million)

Incidentally, the year 2017 witnessed the overall protein A resins market bagging a valuation of USD 510 million. The vertical is expected to continue its upward growth trajectory in the ensuing years, extensively aided by significant investments and changing R&D trends. An instance bearing testimony to the aforementioned statement is that of Creative Diagnostics, a leading supplier of healthcare research products that has recently launched a new product line of ready-to-use IgM purification reagents. According to reports, these new reagents that guarantee purity & stability, will be particularly used for life science applications and will be made available to researchers all over the world.

Industry experts deem that Protein A & G chromatography continues to lead the life science industries for the purification of IgG. However, in the light of the fact that these methods have proved unsuitable for the purification of IgM antibodies, Creative Diagnostics’ new product portfolio is expected to stimulate protein A resins market trends from antibody purification. Reports in fact affirm that with perpetual developments in the antibody field and increasing demand for therapeutics, antibody purification accounted for the largest revenue share of protein A resins industry in 2017.

Get a Sample Copy of this Report https://www.gminsights.com/request-sample/detail/1146

Speaking along similar lines, the increasing demand for monoclonal antibodies for research and management of chronic diseases from clinical research labs have rendered a positive impact on protein A resins industry share. In fact, if reports are to be believed, clinical research laboratories are touted to be the fastest growing end-use segment of this business sphere. Biopharmaceutical firms form a part of another major end-use segment – these firms extensively uses protein A resins for large-scale purification of monoclonal antibodies. Biopharma firms are likely to witness further lucrative growth ahead as several industry players are putting efforts in launching innovative resins that can reduce costs while improving overall efficacy.

The globally renowned pharmaceutical company Teva has created quite some buzz in protein A resins market lately, claiming that it has increased the life of its Protein A resin thereby reducing costs of manufacturing of monoclonal antibodies. The company has reportedly tweaked its cleaning-in-place (CIP) and sterilization-in-place (SIP) processes that enable a longer life span for its MabSelect SuRe Protein A resins. According to industry experts, increased life of Protein A resin can have direct cost advantage, which in this case accounts for as much as 30% of the total cost of making a monoclonal antibody.

GE Healthcare is another prominent industry player that has launched Protein A resins which it claims to improve monoclonal antibody purification capacity by as much as 40%. Reportedly, the company has introduced MabSelect PrismA and believes that it will be the most preferred option among the biopharmaceutical firms in the capture of monoclonal antibodies. The improved resin is a unique combination of base matrix and a Protein A ligand that enables very high dynamic binding capacities.

This extensive participation of industry players in launching innovative products has indeed proved to be a catalyst in uplifting global protein A resins industry share. These players are further likely to adopt strategies such as partnerships & M&As to garner higher revenue streams and strengthen their footprints in protein A resins market. Experts deem that protein A resins are seen as the gold-standard in monoclonal antibody capture, endowed with undeniable efficacy in disrupting the industry landscape. A presumption validating the same is that of Global Market Insights, Inc., that claims global protein A resins market to hit USD 900 million by 2024.

Author Name :Ojaswita Kutepatil

Advertisements